Why was GOG-0213 a negative trial? Editorial
| Authors: | Ehmann, S.; Zivanovic, O.; Chi, D. S. |
| Title: | Why was GOG-0213 a negative trial? |
| Keywords: | cancer chemotherapy; cancer survival; treatment outcome; gene mutation; overall survival; cancer recurrence; bevacizumab; validation process; note; cytoreductive surgery; progression free survival; ovary cancer; histology; cancer mortality; tumor suppressor gene; nicotinamide adenine dinucleotide adenosine diphosphate ribosyltransferase inhibitor; platinum derivative; high risk population; decision making; drug sensitivity; ethnicity; predictive value; mortality rate; low risk population; human; positron emission tomography-computed tomography |
| Journal Title: | Journal of Gynecologic Oncology |
| Volume: | 32 |
| Issue: | 1 |
| ISSN: | 2005-0380 |
| Publisher: | Korean Soc Gynecology Oncology & Colposcopy |
| Date Published: | 2021-01-01 |
| Start Page: | e19 |
| Language: | English |
| DOI: | 10.3802/jgo.2021.32.e19 |
| PUBMED: | 33300314 |
| PROVIDER: | scopus |
| PMCID: | PMC7767651 |
| DOI/URL: | |
| Notes: | Note -- Export Date: 1 February 2021 -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
